Citation Impact
Citing Papers
Engineered receptors for soluble cellular communication and disease sensing
2024 StandoutNatureNobel
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity
2005
Striking Oxygen Sensitivity of the Peptidylglycine α-Amidating Monooxygenase (PAM) in Neuroendocrine Cells
2015 StandoutNobel
Paracrine Activation of Hepatic CB1 Receptors by Stellate Cell-Derived Endocannabinoids Mediates Alcoholic Fatty Liver
2008
Chapter 7 Cannabinoid Receptor CB1 Antagonists
2009
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
2005 Standout
Interactions between the microbiota, immune and nervous systems in health and disease
2017 Standout
Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs
2004
The anti‐obesity effect of rimonabant is associated with an improved serum lipid profile
2004
Descending control of pain
2002 Standout
Bradykinin Induces Interleukin‐6 Expression in Astrocytes Through Activation of Nuclear Factor‐κB
1999
Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice
2003
Structure and function of the blood–brain barrier
2009 Standout
Ethanol self-administration and ethanol conditioned place preference are reduced in mice lacking cannabinoid CB1 receptors
2005
The endocannabinoid system, eating behavior and energy homeostasis: The end or a new beginning?
2010
ETHANOL INDUCES HIGHER BEC IN CB1 CANNABINOID RECEPTOR KNOCKOUT MICE WHILE DECREASING ETHANOL PREFERENCE
2004
Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors
2006
Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions
2007
Inverse agonism and neutral antagonism at cannabinoid CB1 receptors
2004
Endocannabinoids and the control of energy balance
2006
PRESTO-Tango as an open-source resource for interrogation of the druggable human GPCRome
2015
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
2006
N‐Heterocyclic Carbenes as Organocatalysts
2007 Standout
Influence of nootropic and antidepressive drugs on open field and running wheel behavior in spontaneously high and low active mice
1994
Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects
2011 Standout
Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes
2013
Design and Synthesis of a Homogeneous Erythropoietin Analogue with Two Human Complex‐Type Sialyloligosaccharides: Combined Use of Chemical and Bacterial Protein Expression Methods
2009 StandoutNobel
The endocannabinoid system and its therapeutic exploitation
2004
Synergistic effects of cannabinoid inverse agonist AM251 and opioid antagonist nalmefene on food intake in mice
2004
Chemical models of epilepsy with some reference to their applicability in the development of anticonvulsants
1992
Neurotensin-Induced Myocardial Noradrenergic Effects in Spontaneously Hypertensive Rats
2006
GABAA Receptor Channels
1994 Standout
Indigenous Bacteria from the Gut Microbiota Regulate Host Serotonin Biosynthesis
2015 Standout
Endocannabinoids in liver disease
2010
Obesity
2005 Standout
Interleukin-6 expression and regulation in astrocytes
1999
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
The cannabinoid system: a role in both the homeostatic and hedonic control of eating?
2003
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
2006 Standout
The novel object recognition memory: neurobiology, test procedure, and its modifications
2011 Standout
New insights into copper monooxygenases and peptide amidation: structure, mechanism and function
2000
The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review
2003 Standout
Conus Venom Peptide Pharmacology
2012
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
2011 Standout
Organocatalytic Ring-Opening Polymerization
2007 Standout
Neurotensin and neurotensin receptors
1999
Mechanisms of Hepatic Fibrogenesis
2008 Standout
A within-trial cost-effectiveness analysis of primary care referral to a commercial provider for weight loss treatment, relative to standard care—an international randomised controlled trial
2012 Standout
Cannabinoid (CB)1 receptor antagonist, AM 251, causes a sustained reduction of daily food intake in the rat
2004
The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin
2007 Standout
The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food
2004
Post-translational modifications in the context of therapeutic proteins
2006
Diurnal changes in actin mRNA levels and incorporation of35S-methionine into actin in the rat hypothalamus
1990
The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from β3-adrenoceptor agonists
2008
The neural basis of psychedelic action
2022 Standout
Pineal Melatonin: Cell Biology of Its Synthesis and of Its Physiological Interactions*
1991 Standout
The metabolic syndrome—a new worldwide definition
2005 Standout
Mechanisms and Functions of Inflammasomes
2014 Standout
Integrated physiology and pathophysiology of CB1-mediated effects of the endocannabinoid system
2007
Postsynthetic modification of metal–organic frameworks
2009 Standout
Neurotensin and pain modulation
2006
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
2005
CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity
2004
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
2011 Standout
Internalization and recycling properties of neurotensin receptors
2006
The Biosynthesis, Fate and Pharmacological Properties of Endocannabinoids
2005
Cocaine- and Amphetamine-Related Transcript Is Involved in the Orexigenic Effect of Endogenous Anandamide
2005
Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats
2006
Synthetic and plant‐derived cannabinoid receptor antagonists show hypophagic properties in fasted and non‐fasted mice
2009
Astrocyte–endothelial interactions at the blood–brain barrier
2005 Standout
The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis
2003
Ghrelin: Structure and Function
2005 Standout
Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors
2005
Endocannabinoids in the regulation of appetite and body weight
2005
Integration of Endocannabinoid and Leptin Signaling in an Appetite-Related Neural Circuit
2005
Inflammasomes: mechanism of action, role in disease, and therapeutics
2015 Standout
Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing
2014 Standout
Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control
2009
CB1 cannabinoid receptor‐mediated modulation of food intake in mice
2005
Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients
2006
The obesity pipeline: current strategies in the development of anti-obesity drugs
2006
Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice
2003
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
2008 Standout
Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice
2004
Molecular imaging of gene expression and protein function in vivo with PET and SPECT
2002
Human Studies of Cannabinoids and Medicinal Cannabis
2005
Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH)
2005
Endocannabinoid control of food intake and energy balance
2005
Dietary (Poly)phenolics in Human Health: Structures, Bioavailability, and Evidence of Protective Effects Against Chronic Diseases
2012 Standout
Click Chemistry for Drug Development and Diverse Chemical–Biology Applications
2013 Standout
GENETICS OF CIRCADIAN RHYTHMS
1990 StandoutNobel
Pathophysiology of Human Visceral Obesity: An Update
2013 Standout
A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9
2000 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
The Emerging Role of the Endocannabinoid System in Endocrine Regulation and Energy Balance
2005
Room-Temperature Ionic Liquids: Solvents for Synthesis and Catalysis. 2
2011 Standout
Structure and Spectroscopy of Copper−Dioxygen Complexes
2004 Standout
Copper Active Sites in Biology
2014 Standout
Intracerebroventricular administration of cannabinoid CB1 receptor antagonists AM251 and AM4113 fails to alter food-reinforced behavior in rats
2009
Organocatalysis by N-Heterocyclic Carbenes
2007 Standout
??9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist ??9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats
2005
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
TRP Channels and Pain
2013 StandoutNobel
Inflammatory Blockade Restores Adult Hippocampal Neurogenesis
2003 StandoutScience
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
2013
Organocatalytic Reactions Enabled by N-Heterocyclic Carbenes
2015 Standout
Carbon Nanomaterials for Biological Imaging and Nanomedicinal Therapy
2015 Standout
Current and Novel Approaches to the Drug Treatment of Schizophrenia
2001
Circadian rhythms in mammalian neurotransmitter receptors
1987
Controlled Ring-Opening Polymerization of Lactide and Glycolide
2004 Standout
The CB1 receptor antagonist rimonabant reverses the diet‐induced obesity phenotype through the regulation of lipolysis and energy balance
2005
Efficient Transesterification/Acylation Reactions Mediated byN-Heterocyclic Carbene Catalysts
2003
A Dialogue between the Immune System and Brain, Spoken in the Language of Serotonin
2012
CANNABINOID RECEPTORS AS THERAPEUTIC TARGETS
2005
Microglial M1/M2 polarization and metabolic states
2015 Standout
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity
2005
Regulation, Function, and Dysregulation of Endocannabinoids in Models of Adipose and β-Pancreatic Cells and in Obesity and Hyperglycemia
2006
Activation of the Peripheral Endocannabinoid System in Human Obesity
2005
Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity
2006
Endocannabinoids and Food Intake: Newborn Suckling and Appetite Regulation in Adulthood
2005
Works of Peter Keane being referenced
Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells
1998
Effect of serotonin on cytokine mRNA expression in rat hippocampal astrocytes
1996
Cerebral-activating (EEG) properties of two inverse agonists and of an antagonist at the benzodiazepine receptor in the rat
1989
Stimulation of the β3-Adrenoceptor as a Novel Treatment Strategy for Anxiety and Depressive Disorders
2007
Niaprazine, a selective brain catecholamine depletor☆
1979
Genetic studies of daily variations of first-step enzymes of monoamines metabolism in the brain of inbred strains of mice and hybrids. II. Daily variations of tyrosine hydroxylase activity in the locus coeruleus
1980
Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice
2003
EEG effects of IV infusion of pentylenetetrazol in rats: A model for screening and classifying antiepileptic compounds
1985
SR146131: A New Potent, Orally Active, and Selective Nonpeptide Cholecystokinin Subtype 1 Receptor Agonist. II: In Vivo Pharmacological Characterization
1999